Society for Immunotherapy of Cancer

Visit us at SITC 2019

At Gaylord National Hotel & Convention Center, Prince Georges, MD

November 6-10

Talk with one of our scientists at booth 630

Take a look at our latest science at our Posters
(Abstract ID:P75 and P359)

Find out how partnering with us will fast forward your drug discovery and approval pipeline

Stop by our booth to learn if you qualify for a highly discounted pilot program.


Meet immunoSCAPE at ITOC6 in Vienna!

Click here to learn more about this conference.

Keystone Symposia on Molecular and Cellular Biology

Dr Newell and Dr Bonamy to speak at the Keystone Symposia – Cancer Vaccines

Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.


Dr. Evan Newell

Dr Newell presentation at the Annual Meeting of the Japanese Society for Immunology

Click here to learn more about this presentation.

immunoSCAPE to present at ESMO Asia 2018

ESMO Asia 2018 will keep oncology professionals in the Asia-Pacific region up to date with the fast pace of oncology science and education, and provide important networking opportunities with international peers.


Society for Immunotherapy of Cancer

Meet immunoSCAPE and see our data at the SITC 2018 Annual Meeting!

As a benefit for attending the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of the general public, but did not register to attend a Pre-Conference program or the 33rd Annual Meeting, the materials are now available by clicking the links below.


Meet us at the NeoAg Summit in Boston!

The 4th annual NeoAg Summit is returning to Boston this November to provide your team with one all-inclusive forum to successfully target tumor-specific neoantigens and bring to market personalized cancer vaccines and cellular therapies.


immunoSCAPE will be at the ESMO 2018 Congress

A multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress featured a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS). 


immunoSCAPE will be presenting at the Advances in Immuno-Oncology USA Congress 2018

Oxford Global’s R&D US Series features 3 outstanding programmes: our long-running 5th Annual Drug Discovery and Chemistry USA Congress, the 3rd Annual Biomarkers & Precision Medicine USA Congress, and fast-emerging Advances in Immuno-Oncology USA Congress.


immunoSCAPE will be presenting at the Biomarkers & Immuno-Oncology World Congress 2018 in Boston!

The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival benefits that may be unavailable with current approaches. The Second Annual Combination Immunotherapy meeting will explore the most effective combinations of immunotherapy with conventional cancer therapy, with other immunotherapy or with targeted therapy. Coverage will include understanding the mechanism of action, managing toxicity, strategies to design synergistic combinations, biomarker development and case studies of ongoing combination immunotherapy studies from the leading researchers in industry and academia.